Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esomeprazole for frequent heartburn
NCT01370525Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2011
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastroesophageal reflux disease (GERD) comparing Esomeprazole 20 mg with Placebo (2 arms). Primary endpoint: Percentage of Heartburn Free 24 Hour Days During 14 Days of Randomized Treatment. Started Aug 2011; status: completed.
02
Drugs
esomeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT01370525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01370525.